RCEL AVITA MEDICAL INC revenue, earnings and financials

For the quarter ended June 30, 2026, AVITA MEDICAL INC reported revenue of $21.7M (up 17.8% from a year earlier), net income of −$7.66M and diluted EPS of −$0.25; over the last four quarters revenue was $75.6M and net income −$43.1M; for the fiscal year ended December 2025 revenue was $71.6M, up 11.5% on the year before.

RCEL annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $71.6M, gross profit $58.8M, operating income −$42.5M, net income −$48.6M (margin -67.8%), EPS −$1.74
• Fiscal year ended Dec 2024: revenue $64.3M, gross profit $55.2M, operating income −$56.6M, net income −$61.8M (margin -96.3%), EPS −$2.39
• Fiscal year ended Dec 2023: revenue $50.1M, gross profit $42.4M, operating income −$42.7M, net income −$35.4M (margin -70.6%), EPS −$1.40
• Fiscal year ended Dec 2022: revenue $34.4M, gross profit $28.4M, operating income −$27.5M, net income −$26.7M (margin -77.5%), EPS $1.07
• Fiscal year ended Jun 2021: revenue $29.2M, gross profit $23.3M, operating income −$26.5M, net income −$26.6M (margin -90.9%), EPS $1.17

RCEL quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $21.7M (up 17.8% year over year), net income −$7.66M, EPS −$0.25
• Quarter ended Mar 31, 2026: revenue $19.3M (up 4.0% year over year), net income −$10.6M, EPS −$0.35
• Quarter ended Dec 31, 2025 (from the annual report): revenue $17.6M (down 4.3% year over year), net income −$11.6M, EPS −$0.37
• Quarter ended Sep 30, 2025: revenue $17.1M (down 12.7% year over year), net income −$13.2M, EPS −$0.46
• Quarter ended Jun 30, 2025: revenue $18.4M (up 21.2% year over year), net income −$9.92M, EPS −$0.38
• Quarter ended Mar 31, 2025: revenue $18.5M (up 66.7% year over year), net income −$13.9M, EPS −$0.53
• Quarter ended Dec 31, 2024 (from the annual report): revenue $18.4M (up 29.7% year over year), net income −$11.6M, EPS −$0.44
• Quarter ended Sep 30, 2024: revenue $19.5M (up 43.2% year over year), net income −$16.2M, EPS −$0.62
• Quarter ended Jun 30, 2024: revenue $15.2M (up 29.3% year over year), net income −$15.4M, EPS −$0.60
• Quarter ended Mar 31, 2024: revenue $11.1M (up 5.3% year over year), net income −$18.7M, EPS −$0.73
• Quarter ended Dec 31, 2023 (from the annual report): revenue $14.2M (up 50.1% year over year), net income −$7.07M, EPS −$0.28
• Quarter ended Sep 30, 2023: revenue $13.6M (up 50.1% year over year), net income −$8.71M, EPS −$0.34
• Quarter ended Jun 30, 2023: revenue $11.8M (up 41.0% year over year), net income −$10.4M, EPS −$0.41
• Quarter ended Mar 31, 2023: revenue $10.6M (up 39.9% year over year), net income −$9.22M, EPS −$0.37
• Quarter ended Dec 31, 2022 (from the annual report): revenue $9.46M, net income −$5.35M, EPS $0.22
• Quarter ended Sep 30, 2022: revenue $9.09M (up 29.5% year over year), net income −$5.59M, EPS $0.22
• Quarter ended Jun 30, 2022: revenue $8.34M (down 19.1% year over year), net income −$6.26M, EPS $0.25
• Quarter ended Mar 31, 2022: revenue $7.54M (down 14.0% year over year), net income −$9.46M, EPS $0.38
• Quarter ended Sep 30, 2021: revenue $7.02M, net income −$5.95M, EPS $0.24
• Quarter ended Jun 30, 2021: revenue $10.3M, net income −$4.72M, EPS $0.19

RCEL cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$31.2M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$48.9M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$38.0M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$19.1M, share buybacks n/a
• Fiscal year ended Jun 2021: operating cash flow −$25.9M, share buybacks n/a

RCEL balance sheet

• Jun 30, 2026: cash $9.14M, total assets $47.8M, total liabilities $75.6M, shareholders' equity −$27.8M
• Mar 31, 2026: cash $8.31M, total assets $51.5M, total liabilities $74.7M, shareholders' equity −$23.2M
• Dec 31, 2025: cash $10.2M, total assets $56.4M, total liabilities $73.0M, shareholders' equity −$16.7M, long-term debt $0
• Sep 30, 2025: cash $15.4M, total assets $63.7M, total liabilities $70.4M, shareholders' equity −$6.67M, long-term debt $0
• Jun 30, 2025: cash $12.2M, total assets $58.1M, total liabilities $71.0M, shareholders' equity −$12.9M, long-term debt $42.2M
• Mar 31, 2025: cash $14.9M, total assets $69.6M, total liabilities $74.1M, shareholders' equity −$4.57M, long-term debt $41.5M
• Dec 31, 2024: cash $14.1M, total assets $79.7M, total liabilities $75.0M, shareholders' equity $4.50M, long-term debt $42.2M
• Sep 30, 2024: cash $18.6M, total assets $81.1M, total liabilities $68.6M, shareholders' equity $12.2M, long-term debt $42.5M

What is RCEL's revenue?

AVITA MEDICAL INC reported $75.6M of revenue over its last four quarters, through June 30, 2026.

Is RCEL profitable?

No. AVITA MEDICAL INC lost $43.1M over the last four quarters.

What is RCEL's EPS?

Diluted earnings per share over the last four quarters were −$1.43; −$0.25 in the latest quarter.

RCEL ownership and insider trades · All stocks